Loading
A phase 2 trial of SYS6010, osimertinib, pemetrexed, cisplatin and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07256509 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 120 participants, started 2025-11-30 and due to reach its primary completion in 2026-11-30. Interventions recorded: SYS6010; Osimertinib; Pemetrexed; Cisplatin; Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Major Pathological Response (MPR) Rate; Pathological Complete Response (pCR) Rate; Downstaging from N2 to N0/N1 or N1 to N0 at the time of surgery. Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-squamous non-small cell lung cancer, staged as resectable or potentially resectable Stage II-IIIB disease according to the International Association for the Study of Lung Cancer (IASLC) 8th Edition TNM staging criteria;". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SYS6010, CSPC Pharmaceutical Group, Osimertinib, EGFR-mutated non-small-cell lung cancer and the tag lung-deep-dive.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/